NCT07341893Completed
Sacubitril-valsartan in Patients With Heart Failure.
Clinical Study Evaluating Efficacy and Safety Sacubitril-valsartan in Patients With Heart Failure.
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The aim of this study is to evaluate the safety and efficacy of Sacubitril -Valsartan in patients with heart failure.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 1 Jan 2026
- Start date
- 1 Aug 2025
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Damanhour University
- Diseases
- Heart failure
- NCT number
- NCT07341893
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 1 Aug 2025 to the primary completion date, 1 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active infection.
- Congenital heart disease.
- Autoimmune disorders or connective tissue disorders.
Lab values
- CKD with GFR \< 20 ml/min/1.73
- Serum potassium \< 5.5 mmol / L.
Other
- Pregnant or lactating women
- Severe hepatic dysfunction.
Who the study is looking for
- Age ≥ 18 years old for both genders.
- LV ejection fraction (LVEF) ≤40%.
- Heart failure patients with NYHA grade II-IV.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Damanhur Medical National Institute Coordinator of this site? Confirm its status | Damanhūr | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.